Single Bevacizumab Dose Sustains Trabeculectomy Success
A study found that a single dose of intravitreal bevacizumab during trabeculectomy significantly improved surgical success over three years compared to a placebo. Patients receiving bevacizumab had a lower need for topical intraocular pressure-lowering drops. The results suggest that the benefits of bevacizumab persist long-term in glaucoma surgery.
- ▪Intravitreal bevacizumab was associated with more durable surgical success over three years compared to placebo.
- ▪At 36 months, 92.3% of patients receiving bevacizumab achieved complete success compared to 71.2% in the placebo group.
- ▪Fewer patients who received bevacizumab required topical intraocular pressure-lowering drops at most postoperative visits.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/single-bevacizumab-dose-sustains-trabeculectomy-success-2026a1000g4t?src=rss |
| Publication time | Tue, 19 May 2026 03:17:16 EDT |
| Retrieval time | 2026-05-19T07:34:57.437Z |
| Last seen | 2026-05-19T07:34:57.437Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | EHRTsSFw2UVP |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Compared with placebo, intravitreal bevacizumab administered as a single intraoperative dose during trabeculectomy with mitomycin C was associated with more durable surgical success over 3 years and a reduced need for topical intraocular pressure-lowering eye drops.METHODOLOGY:Researchers conducted a 3-year follow-up study of a clinical trial to test whether a single intravitreal injection of bevacizumab during trabeculectomy continued to improve surgical success.Between July 2016 and September 2018, 131 patients who needed primary or redo trabeculectomy or phacotrabeculectomy for progressive glaucoma were enrolled and randomly assigned to receive a single intraoperative intravitreal injection of bevacizumab (n = 65; mean age, 77.7 years; 56.9% male) or placebo (n = 66; mean age,…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
